22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › KalVista Pharmaceuticals, Inc. › 2024-2025

KalVista Pharmaceuticals, Inc. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and KalVista Pharmaceuticals, Inc.’s Form 8-K, filed October 4, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 140Asset managers, any item
  • 626Fund votes
  • October 3, 2024Meeting date

Results at a glance

Meeting of October 3, 2024: 4 items on KalVista Pharmaceuticals, Inc.’s Form 8-K, filed October 4, 2024: 4 passed (calculated).

Dissent

Significant dissent: 1 director (37.7% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore KalVista Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by KalVista Pharmaceuticals, Inc.

These tallies are KalVista Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed October 4, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

KalVista Pharmaceuticals, Inc. — official shareholder meeting results, meeting held October 3, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: William Fairey 30,169,349872,39833,171 --8,328,823 97%Passed (calculated)—
Elect Director: Nancy Stuart 19,324,27711,717,48433,157 --8,328,823 62%Passed (calculated)—
2. Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending April 30, 2025 39,323,44346,85833,440 --0 99.9%Passed (calculated)—
3. Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers 26,578,8054,459,36336,750 --8,328,823 86%Passed (calculated)—

Source: KalVista Pharmaceuticals, Inc., Form 8-K, filed with the SEC on October 4, 2024 — read the filing on EDGAR.

How asset managers voted at the KalVista Pharmaceuticals, Inc. 2024-2025 meeting

140 asset managers disclosed a vote on at least one KalVista Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Nancy Stuart

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

62% Majority: yes · of votes cast

FOR 62%AGAINST
FOR: 19,324,277AGAINST: 11,717,484
Details: description as filed, official tally, votes by 41 asset managers

Description as filed by funds: The election of two Class III directors to hold office until the earliest of our 2027 annual meeting of stockholders and such individual's death, resignation or removal and the election and qualification of his or her successor: NANCY STUART

KalVista Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Nancy Stuart”): 19,324,277 for, 11,717,484 against, per its Form 8-K filed October 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 62% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 5,556,918 for, 990,289 against.

FORAGAINST
FOR: 5,556,918AGAINST: 990,289
Largest asset managers voting on “The election of two Class III directors to hold office until the earliest of our 2027 annual meeting of stockh” at KalVista Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group3,031,4950 00For
Vanguard1,927,9030 00For
BlackRock353,1470 00For
FINANCIAL INVESTORS TRUST0278,261 00Against
Principal0184,171 00Against
Charles Schwab0110,720 00Against
Russell Investments100,1740 00For
DRIEHAUS MUTUAL FUNDS074,868 00Against
Advisors' Inner Circle Fund III11157,520 00Against
Equitable14,98942,450 00Mixed
Northern Trust49,5140 00For
RBB FUND, INC.039,035 00Against
QUANTITATIVE MASTER SERIES LLC33,1170 00For
Lincoln Financial030,945 00Against
Brinker Capital Destinations Trust025,783 00Against
Fidelity24,0160 00For
Global X020,995 00Against
Dimensional018,820 00Against
John Hancock014,851 00Against
Pacific Life13,5040 00For
American Century013,095 00Against
Brighthouse012,559 00Against
FORUM FUNDS II011,509 00Against
Jackson National08,893 00Against
ProShares08,067 00Against

Showing the 25 largest of 41 asset managers. All 41 are in the interactive database (link above).

Elect Director: William Fairey

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 30,169,349AGAINST: 872,398
Details: description as filed, official tally, votes by 41 asset managers

Description as filed by funds: The election of two Class III directors to hold office until the earliest of our 2027 annual meeting of stockholders and such individual's death, resignation or removal and the election and qualification of his or her successor: WILLIAM FAIREY

KalVista Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: William Fairey”): 30,169,349 for, 872,398 against, per its Form 8-K filed October 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 6,079,664 for, 467,543 against.

FOR
FOR: 6,079,664AGAINST: 467,543
Largest asset managers voting on “The election of two Class III directors to hold office until the earliest of our 2027 annual meeting of stockh” at KalVista Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group3,031,4950 00For
Vanguard1,927,9030 00For
BlackRock353,1470 00For
FINANCIAL INVESTORS TRUST0278,261 00Against
Principal0184,171 00Against
Charles Schwab110,7200 00For
Russell Investments100,1740 00For
DRIEHAUS MUTUAL FUNDS74,8680 00For
Advisors' Inner Circle Fund III57,6310 00For
Equitable57,4390 00For
Northern Trust49,5140 00For
RBB FUND, INC.39,0350 00For
QUANTITATIVE MASTER SERIES LLC33,1170 00For
Lincoln Financial30,9450 00For
Brinker Capital Destinations Trust25,7830 00For
Fidelity24,0160 00For
Global X20,9950 00For
Dimensional18,8200 00For
John Hancock14,8510 00For
Pacific Life13,5040 00For
American Century13,0950 00For
Brighthouse12,5590 00For
FORUM FUNDS II11,5090 00For
Jackson National8,8930 00For
ProShares8,0670 00For

Showing the 25 largest of 41 asset managers. All 41 are in the interactive database (link above).

Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 6 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%AGAINST
FOR: 26,578,805AGAINST: 4,459,363

Prior year: 88.3% for (September 26, 2023 meeting) ▼ 2.7 pts

Details: description as filed, official tally, votes by 139 asset managers

Description as filed by funds: Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as disclosed in the Proxy Statement.

KalVista Pharmaceuticals, Inc.’s own tally for this item (“3. Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers”): 26,578,805 for, 4,459,363 against, per its Form 8-K filed October 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 41 asset managers voting on “Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as d” at KalVista Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group03,031,495 00Against
Vanguard1,927,9030 00For
BlackRock353,1470 00For
FINANCIAL INVESTORS TRUST278,2610 00For
Principal184,1710 00For
Charles Schwab110,7200 00For
Russell Investments0100,174 00Against
DRIEHAUS MUTUAL FUNDS74,8680 00For
Advisors' Inner Circle Fund III11157,520 00Against
Equitable57,4390 00For
Northern Trust49,5140 00For
RBB FUND, INC.39,0350 00For
QUANTITATIVE MASTER SERIES LLC33,1170 00For
Lincoln Financial30,200745 00For
Brinker Capital Destinations Trust25,7830 00For
Fidelity24,0160 00For
Global X020,995 00Against
Dimensional018,820 00Against
John Hancock14,8510 00For
Pacific Life13,5040 00For
American Century013,095 00Against
Brighthouse12,5590 00For
FORUM FUNDS II11,5090 00For
Jackson National08,893 00Against
ProShares8,0670 00For

Fund voting reports, all 41 managers: 3,285,975 for, 3,261,232 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 112 asset managers voting on “Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as d” at KalVista Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
VR Adviser, LLC6,249,7310 00For
SUVRETTA CAPITAL MANAGEMENT, LLC3,609,2370 00For
Capital Group2823,031,495 00Against
ADAGE CAPITAL PARTNERS GP, L.L.C.1,800,0000 00For
Vestal Point Capital, LP1,595,3970 00For
GREAT POINT PARTNERS LLC1,290,3790 00For
BlackRock970,74718,352 00For
MPM BioImpact LLC905,6240 00For
DAFNA Capital Management LLC723,6780 00For
PERCEPTIVE ADVISORS LLC500,0000 00For
EMERALD MUTUAL FUND ADVISERS TRUST462,4320 00For
State Street445,4340 00For
SILVERARC CAPITAL MANAGEMENT, LLC380,1290 00For
DRIEHAUS CAPITAL MANAGEMENT LLC344,7340 00For
EMERALD ADVISERS, LLC336,7860 00For
Nicholas Investment Partners, LP0190,129 00Against
Northern Trust160,3910 00For
Russell Investments0135,684 00Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC116,0680 00For
Woodline Partners LP110,9500 00For
Charles Schwab110,7200 00For
UBS103,2014,433 00For
Wellington097,328 00Against
First Turn Management, LLC086,791 00Against
Vanguard82,2820 00For

Institutional-manager reports, all 112 managers: 20,736,534 for, 3,933,720 against, 32,407 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 39,323,443AGAINST: 46,858

Prior year: 100.0% for (September 26, 2023 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 41 asset managers

Description as filed by funds: THE RATIFICATION OF THE SELECTION, BY THE AUDIT COMMITTEE OF OUR BOARD, OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING APRIL 30, 2025.

KalVista Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending April 30, 2025”): 39,323,443 for, 46,858 against, per its Form 8-K filed October 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 6,547,096 for, 111 against.

FOR
FOR: 6,547,096AGAINST: 111
Largest asset managers voting on “THE RATIFICATION OF THE SELECTION, BY THE AUDIT COMMITTEE OF OUR BOARD, OF DELOITTE & TOUCHE LLP AS OUR INDEPE” at KalVista Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group3,031,4950 00For
Vanguard1,927,9030 00For
BlackRock353,1470 00For
FINANCIAL INVESTORS TRUST278,2610 00For
Principal184,1710 00For
Charles Schwab110,7200 00For
Russell Investments100,1740 00For
DRIEHAUS MUTUAL FUNDS74,8680 00For
Advisors' Inner Circle Fund III57,520111 00For
Equitable57,4390 00For
Northern Trust49,5140 00For
RBB FUND, INC.39,0350 00For
QUANTITATIVE MASTER SERIES LLC33,1170 00For
Lincoln Financial30,9450 00For
Brinker Capital Destinations Trust25,7830 00For
Fidelity24,0160 00For
Global X20,9950 00For
Dimensional18,8200 00For
John Hancock14,8510 00For
Pacific Life13,5040 00For
American Century13,0950 00For
Brighthouse12,5590 00For
FORUM FUNDS II11,5090 00For
Jackson National8,8930 00For
ProShares8,0670 00For

Showing the 25 largest of 41 asset managers. All 41 are in the interactive database (link above).

Largest KalVista Pharmaceuticals, Inc. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 43,215,472 shares outstanding at the time of that meeting.

Fund voting reports: top KalVista Pharmaceuticals, Inc. shareholders by shares voted on “Approval, on a non-binding advisory basis, of the compensation paid by us to our named…”, 2024-2025
#Asset manager % of shares outstanding
1Capital Group 7.01%
2Vanguard 4.46%
3BlackRock 0.82%
4FINANCIAL INVESTORS TRUST 0.64%
5Principal 0.43%
6Charles Schwab 0.26%
7Russell Investments 0.23%
8DRIEHAUS MUTUAL FUNDS 0.17%
9Advisors' Inner Circle Fund III 0.13%
10Equitable 0.13%
Institutional-manager reports: top KalVista Pharmaceuticals, Inc. shareholders by shares voted on “Approval, on a non-binding advisory basis, of the compensation paid by us to our named…”, 2024-2025
#Asset manager % of shares outstanding
1VR Adviser, LLC 14.46%
2SUVRETTA CAPITAL MANAGEMENT, LLC 8.35%
3Capital Group 7.02%
4ADAGE CAPITAL PARTNERS GP, L.L.C. 4.17%
5Vestal Point Capital, LP 3.69%
6GREAT POINT PARTNERS LLC 2.99%
7BlackRock 2.29%
8MPM BioImpact LLC 2.10%
9DAFNA Capital Management LLC 1.67%
10PERCEPTIVE ADVISORS LLC 1.16%

Reported KalVista Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

KalVista Pharmaceuticals, Inc. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Entities affiliated with Venrock Healthcare Capital Partners III, L.P.5,012,796 11.60%Proxy statement (DEF 14A), table as of August 6, 2025
Venrock Healthcare Capital Partners III, L.P.5,012,796 11.60%Schedule 13G, filed February 3, 2025
TANG CAPITAL MANAGEMENT, LLC4,941,798 11.44%Schedule 13G, filed May 15, 2025
Tang Capital Partners, LP4,941,798 11.44%Proxy statement (DEF 14A), table as of August 6, 2025
Entities affiliated with Frazier Life Sciences Public Fund, L.P.4,887,867 11.31%Proxy statement (DEF 14A), table as of August 6, 2025
Entities affiliated with Suvretta Capital Management, LLC4,328,904 10.02%Proxy statement (DEF 14A), table as of August 6, 2025
Capital World Investors3,177,587 7.35%Schedule 13G, filed May 13, 2025
BlackRock3,151,735 7.29%Form 13F, quarter ended March 31, 2025
SilverArc Capital Management, LLC2,876,407 6.66%Schedule 13G, filed May 13, 2026
Vanguard Group2,298,598 5.32%Form 13F, quarter ended March 31, 2025

Percentages above are of 43,215,472 shares outstanding, as reported by KalVista Pharmaceuticals, Inc. on its Form 10-Q dated August 26, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At KalVista Pharmaceuticals, Inc.'s shareholder meeting held October 3, 2024, in the 2024-2025 proxy season, 140 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 626 separate fund positions. On the most widely held item on that ballot — Approval, on a non-binding advisory basis, of the compensation paid by us to our named… — FOR was 86% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: KalVista Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on October 4, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KalVista Pharmaceuticals, Inc.’s 10-Q dated August 26, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

KalVista Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “KalVista Pharmaceuticals, Inc. 2024 Annual Meeting (2024-2025 season)”, https://proxyvotesnow.com/company/kalvista-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.